Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemorubicin intrahepatic artery plus cisplatin in unresectable hepatocellular carcinoma
2005-000731-26Phase 2Completed
- Sponsor
- Nerviano Medical Sciences
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nemorubicin and cisplatin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Nerviano Medical Sciences. Primary endpoints: Maximum tolerated dose, Dose-limiting toxicities and 3 more. Started Jun 2005; status: completed.
02
Drugs
nemorubicincisplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2005-000731-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000731-26.